TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7324942

Group type: EXPERIMENTAL
Intervention: 10-day treatment with sulfafurazole
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 42-day treatment
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 10-day treatment
Number of subjects: 235
Study: 30679107

Group type: EXPERIMENTAL
Intervention: Four courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Eight courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Four courses of S-1
Number of subjects: 590

Group type: COMPARATOR
Intervention: Eight courses of S-1
Number of subjects: 590
Study: 28093609

Group type: EXPERIMENTAL
Intervention: Distal femoral locking plate alone (group I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Distal femoral locking plate with cerclage cable (group II)
Number of subjects: 21
Study: 26858958

Group type: EXPERIMENTAL
Intervention: Peer support intervention (additional to DMP), running over 24 months, including peer supporter recruitment, training, weekly physical exercise meetings, and monthly discussions on diabetes-related topics.
Number of subjects: 337

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 337
Study: 24507553

Group type: EXPERIMENTAL
Intervention: Mental Health Online e-learning modules
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 154
Study: 22723469

Group type: EXPERIMENTAL
Intervention: Nasal swab tested by rRT‐PCR
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab tested by rRT‐PCR
Number of subjects: 240
Study: 20873252

Group type: EXPERIMENTAL
Intervention: panto‐magnesium pearl baths
Number of subjects: 49

Group type: COMPARATOR
Intervention: magnetotherapy, manual massage and exercise therapy
Number of subjects: 49
Study: 17407654

Group type: EXPERIMENTAL
Intervention: Telephone reminder calls
Number of subjects: 504

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Not contactable group
Number of subjects: 504
Study: 15910951

Group type: EXPERIMENTAL
Intervention: Home visitation by nurses in addition to standard treatment
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 163
Study: 11876704

Group type: EXPERIMENTAL
Intervention: Bismuth-based triple regimens (treatment group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment (no treatment group)
Number of subjects: 27
Study: 10606847

Group type: EXPERIMENTAL
Intervention: Locobase(R) fatty cream containing a mixture of 5% lactic acid and 20% propylene glycol (LPL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Essex(R) (Diprobase(R)) cream (LPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Locobase(R) fatty cream containing 5% urea
Number of subjects: 20

Group type: COMPARATOR
Intervention: Locobase(R) fatty cream containing 20% propylene glycol
Number of subjects: 20
Study: 1289508

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study: 6085375

Group type: EXPERIMENTAL
Intervention: Nitrendipine (2 X 10 to 2 X 20 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Propranolol (2 X 80 to 2 X 160 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 25
Study: 30473390

Group type: EXPERIMENTAL
Intervention: Delayed school start time to 10:00am
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Classroom-based sleep education programme
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of delayed start time and sleep education programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 30309835

Group type: EXPERIMENTAL
Intervention: Tailored, therapist-guided internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 1000
Study: 26201436

Group type: EXPERIMENTAL
Intervention: Coping cards (n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Case management only (n = 32)
Number of subjects: 64
Study: 25620449

Group type: EXPERIMENTAL
Intervention: SB building-level intervention
Number of subjects: 117
Study: 23582138

Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl plus open-label boluses of fentanyl
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (continuous infusion of placebo plus open-label boluses of fentanyl)
Number of subjects: 131
Study: 20872323

Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional oral feeding
Number of subjects: 52
Study: 18394499

Group type: EXPERIMENTAL
Intervention: Myofascial release massage
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (sham treatment with disconnected ultrasound and magnetotherapy equipment)
Number of subjects: 62
Study: 16451396

Group type: EXPERIMENTAL
Intervention: ProME(Epidoxorubicin)CE-CytaBOM (PE-C)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: ProMI(Idarubicin)CE-CytaBOM (PI-C)
Number of subjects: 356

Group type: COMPARATOR
Intervention: ProME(Epidoxorubicin)CE-CytaBOM (PE-C) and ProMI(Idarubicin)CE-CytaBOM (PI-C)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Flexible treatment schedule
Number of subjects: 356

Group type: COMPARATOR
Intervention: Fixed treatment schedule
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Patients with IPI 3-5
Number of subjects: 356
Study: 12920631

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 6
Study: 10805697

Group type: COMPARATOR
Intervention: Shoulder free condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shoulder fixed condition
Number of subjects: 0
Study: 9224834

Group type: EXPERIMENTAL
Intervention: First-order motion stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-order motion stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow second-order stimuli
Number of subjects: 0
Study: 8015881

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (iv 100 mg/kg/d, then oral 50 mg/kg/d after 48 hours afebrile)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Benzylpenicillin (100,000 IU/kg/d) + netilmicin (5 mg/kg/d) + metronidazole (30 mg/kg/d) (iv, then oral metronidazole 30 mg/kg/d)
Number of subjects: 64
Study: 3323609

Group type: EXPERIMENTAL
Intervention: Amino acid infusion with somatostatin and hormone replacement (insulin/glucagon/growth hormone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amino acid infusion alone
Number of subjects: 0
Study: 31530424

Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ (SC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Active-control (AC)
Number of subjects: 61
Study: 29761861

Group type: EXPERIMENTAL
Intervention: ICD plus medical therapy
Number of subjects: 3359

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 3359
Study: 27149561

Group type: EXPERIMENTAL
Intervention: Size modulation standard automated perimetry (SM‐SAP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional standard automated perimetry (C‐SAP)
Number of subjects: 88
Study: 25178073

Group type: EXPERIMENTAL
Intervention: Fixed combination of nebivolol and amlodipine (n=62)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Free combination of nebivolol and amlodipine (n=62)
Number of subjects: 124
Study: 22863282

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 59

Group type: COMPARATOR
Intervention: Scheduled intravenous analgesia (nurse-administered hydromorphone)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 59
Study: 20194309

Group type: EXPERIMENTAL
Intervention: Mobile compression device
Number of subjects: 410

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 410
Study: 18206525

Group type: EXPERIMENTAL
Intervention: Telehome monitoring (video conferencing and phone line transmission of weight, blood pressure, and electrocardiograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehome monitoring
Number of subjects: 0
Study: 15764242

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (non-smokers subgroup)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (non-smokers subgroup)
Number of subjects: 197
Study: 14532151

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 chimeric monoclonal antibody)
Number of subjects: 0
Study: 10561229

Group type: EXPERIMENTAL
Intervention: CDB (cisplatin, dacarbazine, carmustine)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: CDB + TAM (cisplatin, dacarbazine, carmustine + tamoxifen)
Number of subjects: 184
Study: 8673528

Group type: EXPERIMENTAL
Intervention: Didanosine 500 mg/d
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Didanosine 200 mg/d
Number of subjects: 400

Group type: COMPARATOR
Intervention: Zidovudine 600 mg/d
Number of subjects: 400
Study: 1499856

Group type: EXPERIMENTAL
Intervention: Intravenous portal insulin infusion (IPII) via the umbilical vein for 4 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) for 4 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 6540532

Group type: EXPERIMENTAL
Intervention: Moderate dose prednisolone (60 mg/m2/day p.o. for 21 days)
Number of subjects: 73
Study: 30688865

Group type: EXPERIMENTAL
Intervention: Interset Stretching (ISS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 29
Study: 29904126

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (n=49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matching placebo (n=51)
Number of subjects: 100
Study: 27227691

Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide (PEA-um)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 24606997

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham whole-body vibration (SWBV)
Number of subjects: 16
Study: 21683660

Group type: EXPERIMENTAL
Intervention: Blue light therapy (400 lux for 30 minutes per day, Monday through Friday, for 4 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo red light therapy (75 lux)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Blue light therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo red light therapy
Number of subjects: 28
Study: 19357997

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with 0.1 mg.kg(‐1) morphine (Group LM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with 1.5 mg.kg(‐1) tramadol (Group LT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% lidocaine (Group L)
Number of subjects: 90
Study: 17453361

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 or 5 years
Number of subjects: 2738

Group type: COMPARATOR
Intervention: No adjuvant endocrine therapy
Number of subjects: 2738
Study: 15084368

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Inducibility at baseline PVS
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Non-inducible patients
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Inducible patients
Number of subjects: 285
Study: 12205826

Group type: EXPERIMENTAL
Intervention: Personal stereo
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control treatment (nonfunctioning hearing aid)
Number of subjects: 1
Study: 9793750

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital-based rehabilitation
Number of subjects: 0
Study: 2187945

Group type: EXPERIMENTAL
Intervention: MCT diet (40% of energy as medium chain triglycerides)
Number of subjects: 10

Group type: COMPARATOR
Intervention: LCT diet (40% of energy as long chain triglycerides, soybean oil)
Number of subjects: 10
Study: 791197

Group type: EXPERIMENTAL
Intervention: Deanol (dimethylaminoethanol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 30540649

Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide 150 mg twice daily for 16 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Matching placebo for 16 weeks
Number of subjects: 98
Study: 29210011

Group type: EXPERIMENTAL
Intervention: Um‐PEA 600 mg twice daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26008654

Group type: COMPARATOR
Intervention: Placebo (Group-C, n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral tramadol 100 mg (Group-T, n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg (Group-F, n=30)
Number of subjects: 90
Study: 23066987

Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 21975305

Group type: EXPERIMENTAL
Intervention: eCG (500 IU Folligon®)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: eCG-hCG (500 IU Folligon® + 500 IU Chorulon®)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study: 17852302

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (including psychological/cognitive-behavioral components)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable (control group of patients who did not start treatment)
Number of subjects: 50
Study: 16139783

Group type: EXPERIMENTAL
Intervention: Duration production tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration reproduction tasks
Number of subjects: 0
Study: 12674391

Group type: EXPERIMENTAL
Intervention: Interactive voice response system
Number of subjects: 0
Study: 10929741

Group type: EXPERIMENTAL
Intervention: i.v. heparin (5,000 IU bolus + 1,000 IU/h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: i.v. 0.9% NaCl (placebo)
Number of subjects: 18
Study: 8833417

Group type: EXPERIMENTAL
Intervention: Idazoxan (IDZ)
Number of subjects: 3
Study: 1428183

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clarithromycin (maintenance phase)
Number of subjects: 9
Study: 6747977

Group type: EXPERIMENTAL
Intervention: Strep. pneumoniae diagnosed as the cause of pneumonia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No causative organism demonstrated
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diagnosis methods for pneumococcal infection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bacteraemic cases
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Severity of community-acquired pneumococcal pneumonia
Number of subjects: 80
Study: 30861061

Group type: EXPERIMENTAL
Intervention: ZTI-01 (6 g q8h for 7 days)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (4.5 g IV q8h for 7 days)
Number of subjects: 465
Study: 27773347

Group type: EXPERIMENTAL
Intervention: Chewed ticagrelor tablets
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets
Number of subjects: 99

Group type: COMPARATOR
Intervention: Integral ticagrelor tablets
Number of subjects: 99
Study: 26373270

Group type: EXPERIMENTAL
Intervention: HMB-FA (free acid form) administered in capsules
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HMB-FA (free acid form) administered in water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ca-HMB (calcium salt form) administered in capsules
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ca-HMB (calcium salt form) administered in water
Number of subjects: 10
Study: 24530134

Group type: COMPARATOR
Intervention: Conventional group (daily steroids)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pulse group (weekly doses of steroids)
Number of subjects: 19
Study: 22955394

Group type: EXPERIMENTAL
Intervention: 36-mm Delta ceramic-on-ceramic (COC) articulation
Number of subjects: 93

Group type: COMPARATOR
Intervention: common-sized alumina ceramic head on polyethylene liner (COP) articulation
Number of subjects: 93
Study: 20621545

Group type: EXPERIMENTAL
Intervention: Specific ultrasound guided exercises
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: General exercises
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 109
Study: 17213498

Group type: EXPERIMENTAL
Intervention: Telemedicine application (electronic health information support system) for 6 weeks post-discharge
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no telemedicine intervention)
Number of subjects: 184
Study: 15882799

Group type: EXPERIMENTAL
Intervention: IVS1‐21G>A polymorphism in GABRA5 gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haplotype IVS1‐21G>A/IVS2‐26A>T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haplotype IVS1‐21A/IVS2‐26T
Number of subjects: 0
Study: 11922646

Group type: EXPERIMENTAL
Intervention: Modified MAZE operation using intra‐operatively cooled‐tip radiofrequency ablation (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mitral valve replacement alone (group B)
Number of subjects: 30
Study: 9444412

Group type: EXPERIMENTAL
Intervention: Oral fleroxacin 400 mg once a day for 7 days
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cefalexin 500 mg three times daily for 7 days
Number of subjects: 95
Study: 8568534

Group type: EXPERIMENTAL
Intervention: Quantitative spasticity measures (H-reflex testing with and without Achilles tendon vibration, H-reflex testing with and without dorsiflexor contraction, reflex threshold angle, timed toe tapping)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale (MAS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Timed Toe Tapping (TTT)
Number of subjects: 34
Study: 2146967

Group type: EXPERIMENTAL
Intervention: Filtered coffee
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Boiled coffee
Number of subjects: 176

Group type: COMPARATOR
Intervention: No coffee (control group)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Caffeine (75 mg tablets)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 176
Study: 625519

Group type: EXPERIMENTAL
Intervention: 400 Hz pips designated as targets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1600 Hz pips designated as targets
Number of subjects: 12
Study: 31792921

Group type: EXPERIMENTAL
Intervention: Givosiran 2.5 mg/kg, administered subcutaneously monthly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Givosiran
Number of subjects: 0
Study: 30979401

Group type: EXPERIMENTAL
Intervention: Educational program followed by a structured multidisciplinary care program for management of neuropsychiatric symptoms.
Number of subjects: 305

Group type: COMPARATOR
Intervention: Registered nurses compared to other nursing staff.
Number of subjects: 305
Study: 28029329

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg once daily
Number of subjects: 900

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin for 6 months
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: TF levels
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Venous compression from mass
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Hepatobiliary cancer
Number of subjects: 900
Study: 25522664

Group type: EXPERIMENTAL
Intervention: Perinatal Dyadic Psychotherapy (PDP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care plus depression monitoring by phone
Number of subjects: 42
Study: 23360084

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg i.v.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: NaCl (0.9% w/v)
Number of subjects: 19
Study: 20878173

Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Midline incision (Control)
Number of subjects: 205
Study: 19436951

Group type: EXPERIMENTAL
Intervention: Open-door (OD) laminoplasty with unilateral mini-plating
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bilateral cutting (BL) technique with retropositioning of the laminae and bilateral mini-plating
Number of subjects: 13
Study: 16889854

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15832067

Group type: EXPERIMENTAL
Intervention: Self-hypnosis (mean of 2.4 sessions, SD 1.7; range 2-5 sessions) along with standard anti-allergic pharmacological treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (self-hypnosis learned in year 2)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 79
Study: 11981150

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (group C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 68
Study: 9787687

Group type: EXPERIMENTAL
Intervention: Zidovudine/Lamivudine (ZDV/3TC)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Zidovudine/Didanosine (ZDV/ddI)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Didanosine (ddI)
Number of subjects: 471
Study: 7621059

Group type: EXPERIMENTAL
Intervention: High-dose continuous nebulization of albuterol (7.5 mg/h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High-dose intermittent nebulization of albuterol (2.5 mg every 20 minutes for four hours)
Number of subjects: 22
Study: 2534912

Group type: EXPERIMENTAL
Intervention: Sizofiran (Schizophyllan: SPG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28096

Group type: EXPERIMENTAL
Intervention: 10 mg clobazam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg clobazam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29209859

Group type: EXPERIMENTAL
Intervention: Spicae aetheroleum (Spicae ae.)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 30372756

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravitreal aflibercept
Number of subjects: 40